EGFR and neoplasm: Next‐generation sequencing (NGS, Burning Rock, Guangzhou, People's Republic of China) test for a large panel containing 520 oncogenic genes was used for molecular testing of the adrenal biopsy sample, which confirmed the presence of MET (MET proto‐oncogene, receptor tyrosine kinase) gene amplification (copy number 10.3) (Fig 1), in addition to the baseline EGFR exon 19 del with an allele frequency of 47.5%, and tumor mutation burden (TMB) was calculated (7.9 mutations/Mb).